Last reviewed · How we verify
Transdermal delivery system
Mundipharma AB's transdermal delivery system is currently on the market, leveraging a unique mechanism to address its primary indication. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue protection. However, the lack of specified competitors and trial results poses a strategic risk, as it may be challenging to assess the drug's competitive landscape and efficacy compared to emerging alternatives.
At a glance
| Generic name | Transdermal delivery system |
|---|---|
| Sponsor | Mundipharma AB |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (PHASE1)
- Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
- Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause (NA)
- Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (NA)
- Study of ALTO-101 in Patients With Schizophrenia (PHASE2)
- Feasibility of Delivering VergeRx at FQHCs (NA)
- Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |